Doctors’ preference for branded version of cholesterol drug costs US healthcare system $700m a year, study showsBMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e2736 (Published 16 April 2012) Cite this as: BMJ 2012;344:e2736
- Michael Day
Doctors are too easily persuaded to continue prescribing branded drugs by marketing strategies designed to ensure that they do not switch to cheaper generic versions, a new study says.
Yale University researchers cite Abbott’s marketing of its blockbuster cholesterol lowering drug fenofibrate as a key example of a company’s techniques to extend a drug patent. The first formulation of the drug, which is marketed in the United States as TriCor, came off patent in 2002, but the introduction of new formulations allowed a version of it to remain on patent until 2011.
“This continued use of branded formulations, which cost twice as much as generic versions of fenofibrate, imposes an annual cost of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial